Phase II Study of HRS-1893 for Treating Heart Failure With Preserved Ejection Fraction in Adults Aged 40 and Older

What this Trial Is About

Researchers are evaluating the safety and tolerability of the drug HRS-1893 in adults with heart failure with preserved ejection fraction, a condition where the hearts pumping ability is normal but symptoms of heart failure are present. This is a Phase II clinical trial sponsored by Shandong Suncadia Medicine Co., Ltd. The study aims to better understand how HRS-1893 affects patients with this type of heart failure. Participants will be randomly assigned to receive either HRS-1893 tablets or placebo tablets in a double-blind setup, meaning neither participants nor researchers know who receives the active drug. The study includes a 24-week treatment period where participants take the assigned tablets. Throughout the study, researchers will monitor drug levels in the blood and assess various heart function measures to evaluate the impact of the treatment. During the trial, participants will undergo evaluations including blood tests for heart-related proteins, questionnaires assessing heart failure symptoms, and physical tests like the six-minute walk test to measure exercise capacity. Heart function will be checked by echocardiography. Safety will be monitored by recording any adverse events up to 24 weeks. The total participation period covers treatment and follow-up assessments lasting up to around 29 weeks.

A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction